Miraculins amends private placement offering

Miraculins (TSX-V:MOM) has raised the number of units in a previously announced private placement to 10 million from 7.5 million, with the units priced at five cents each instead of seven cents, for gross proceeds of $500,000. Each unit will consist of one common share of the company and one warrant.  Each warrant can be [...]

Dundee starts SQI Diagnostics at buy

The FDA has cleared marketing of SQI Diagnostics’ automated SQiDworks Diagnostics Platform and its lead IgXPLEX assay panel for rheumatoid arthritis in the U.S., prompting Dundee Securities to initiate coverage of the stock with a “buy” rating and a 12-month price target of $6. SQI (TSX-V:SQD) touched a 52-week high of $2.65 in early trading [...]

Waiting on Medicago trial results

In a New Idea of Interest report on Medicago (TSX-V:MDG), Dundee Securities said that if Phase 1 results for its lead H5N1 avian vaccine are positive in December, the company could “establish a leading position in the global effort to find a superior vaccine-production technology.” Analyst David Martin rates the stock “buy (speculative risk)” but [...]

Critical Outcome MOA on COTI-2

Critical Outcome Technologies (TSX-V:COT) for the first time has outlined the specific cellular target and mechanism of action for its lead oncology candidate COTI-2. “We have now demonstrated through a series of key experiments that the Pleckstrin Homology domain of (the protein) AKT/AKT2 is a selective cellular target for COTI-2,” Critical Outcome president Dr. Wayne [...]

Cannasat lighting up THC drug

Twenty-year cancer survivor Sara Lee Irwin is a passionate advocate for the pain relieving benefits of medicinal cannabis drugs and health risks of chronic use of opioid medicines. “Nothing beats opioids for blunt-hammer pain and trauma, but for chronic, life-long pain management, cannabinoids are the better choice,” she says in an exclusive interview with biotuesdays.com. [...]

« Previous Page